Instrument Inactif

Autres langues ChemoCentryx, Inc.

Actions

CCXI

US16383L1061

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Global BMI Index	24/10/22
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P TMI Index	24/10/22
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Biotechnology Select Industry Index	24/10/22
HBM Healthcare rutscht im H1 2022/23 mit 34 Millionen Franken in Verlustzone	21/10/22
Amgen Completes ChemoCentryx Acquisition	20/10/22
CHEMOCENTRYX, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	20/10/22
Chemocentryx, Inc. Announces Executive Changes	20/10/22
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX	20/10/22
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Composite Index	20/10/22
Amgen Inc. completed the acquisition of ChemoCentryx, Inc. from a group of shareholders.	20/10/22
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Biotechnology Index	19/10/22
CHEMOCENTRYX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	18/10/22
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	17/10/22
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	17/10/22
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting	05/10/22
HBM Healthcare erwartet für H1 2022/23 Nettoverlust von rund 34 Mio Fr.	03/10/22
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	28/09/22
CHEMOCENTRYX, INC. : Other Events (form 8-K)	20/09/22
ChemoCentryx Announces TAVNEOS (avacopan) Presentations at Upcoming Medical Conferences	25/08/22
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences	24/08/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ChemoCentryx, Inc.

Actions

CCXI

US16383L1061

Autres langues

Filtres